Distribution of Podoplanin-Positive Tumor Vessels Predicts Disease-Specific Survival of Node-Positive Breast Cancer Patients Treated with Anthracyclines and/or Taxanes

REFERENCES

• Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ. Strategies for subtypes–dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011;22(8):1736–1747.
   PubMed Web of Science ®Google Scholar
• Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M. Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, Nielsen TO. Ki67 index; HER2 status; and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009;101(10):736–750.
   PubMed Web of Science ®Google Scholar
• Horwitz SB. Taxol (paclitaxel): mechanisms of action. Ann Oncol 1994;5(Suppl 6):S3–S6.
   PubMedGoogle Scholar
• Manfredi JJ, Parness J, Horwitz SB. Taxol binds to cellular microtubules. J Cell Biol 1982;94(3):688–696.
   PubMed Web of Science ®Google Scholar
• Barrett-Lee PJ. Growth factor signalling in clinical breast cancer and its impact on response to conventional therapies: a review of chemotherapy. Endocr Relat Cancer 2005;12(Suppl 1):S125–S133.
   PubMedGoogle Scholar
• Watt PM, Hickson ID. Structure and function of type II DNA topoisomerases. Biochem J 1994; 303:681–695.
   PubMed Web of Science ®Google Scholar
• Penault-Llorca F, André F, Sagan C, Lacroix-Triki M, Denoux Y, Verriele V, Jacquemier J, Baranzelli MC, Bibeau F, Antoine M, Lagarde N, Martin AL, Asselain B, Roché H. Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer. J Clin Oncol 2009;27(17):2809–2815.
   PubMed Web of Science ®Google Scholar
• Dumontet C, Krajewska M, Treilleux I, Mackey JR, Martin M, Rupin M, Lafanechère L, Reed JC. BCIRG 001 molecular analysis: prognostic factors in node-positive breast cancer patients receiving adjuvant chemotherapy. Clin Cancer Res 2010;16(15):3988–3997.
   PubMed Web of Science ®Google Scholar
• Schoppmann SF, Bayer G, Aumayr K, Taucher S, Geleff S, Rudas M, Kubista E, Hausmaninger H, Samonigg H, Gnant M, Jakesz R, Horvat R. Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancer. Ann Surg 2004;240(2):306–312.
   PubMed Web of Science ®Google Scholar
• Mohammed RA, Ellis IO, Mahmmod AM, Hawkes EC, Green AR, Rakha EA, Martin SG. Lymphatic and blood vessels in basal and triple-negative breast cancers: characteristics and prognostic significance. Mod Pathol 2011;24(6):774–785.
   PubMed Web of Science ®Google Scholar
• Weidner N. Current pathologic methods for measuring intratumoural microvessel density within breast carcinoma and other solid tumours. Breast Cancer Res Treat 1995;36(2):169–180.
   PubMed Web of Science ®Google Scholar
• Vermeulen PB, Gasparini G, Fox SB, Colpaert C, Marson LP, Gion M, Beliën JA, de Waal RM, Van Marck E, Magnani E, Weidner N, Harris AL, Dirix LY. Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. Eur J Cancer 2002;38(12):1564–1579.
   PubMed Web of Science ®Google Scholar
• Niemiec J, Adamczyk A, Ambicka A, Mucha-Małecka A, Wysocki W, Mituś J, Ryś J. Lymphangiogenesis assessed using three methods is related to tumour grade; breast cancer subtype and expression of basal marker. Pol J Pathol 2012;63(3):165–171.
   PubMed Web of Science ®Google Scholar
• Schoppmann SF, Berghoff A, Dinhof C, Jakesz R, Gnant M, Dubsky P, Jesch B, Heinzl H, Birner P. Podoplanin-expressing cancer-associated fibroblasts are associated with poor prognosis in invasive breast cancer. Breast Cancer Res Treat 2012;134(1):237–244.
   PubMed Web of Science ®Google Scholar
• Pula B, Jethon A, Piotrowska A, Gomulkiewicz A, Owczarek T, Calik J, Wojnar A, Witkiewicz W, Rys J, Ugorski M, Dziegiel P, Podhorska-Okolow M. Podoplanin expression by cancer-associated fibroblasts predicts poor outcome in invasive ductal breast carcinoma. Histopathology 2011;59(6):1249–1260.
   PubMed Web of Science ®Google Scholar
• Khosravi SP, Fernández PI. Tumoral angiogenesis: review of the literature. Cancer Invest. 2008 Feb;26(1):104–108.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Pinilla SM, Sarrió D, Honrado E, Hardisson D, Calero F, Benitez J, Palacios J. Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas. Clin Cancer Res 2006;12(5):1533–1539.
   PubMed Web of Science ®Google Scholar
• Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer. Cancer 2007;109(1):25–32.
   PubMed Web of Science ®Google Scholar
• Yoder BJ, Tso E, Skacel M, Pettay J, Tarr S, Budd T, Tubbs RR, Adams JC, Hicks DG. The expression of fascin; an actin-bundling motility protein; correlates with hormone receptor-negative breast cancer and a more aggressive clinical course. Clin Cancer Res 2005;11(1):186–192.
   PubMed Web of Science ®Google Scholar
• Al-Alwan M, Olabi S, Ghebeh H, Barhoush E, Tulbah A, Al-Tweigeri T, Ajarim D, Adra C. Fascin is a key regulator of breast cancer invasion that acts via the modification of metastasis-associated molecules. PLoS One 2011;6(11):e27339. doi: 10.1371 /journal.pone.0027339.
   PubMedGoogle Scholar
• Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2006;6:392–401.
   PubMed Web of Science ®Google Scholar
• Saharinen P, Tammela T, Karkkainen MJ, Alitalo K. Lymphatic vasculature: development, molecular regulation and role in tumor metastasis and inflammation. Trends Immunol 2004;25:387–395.
   PubMed Web of Science ®Google Scholar
• Cunnick GH, Jiang WG, Gomez KF, Mansel RE. Lymphangiogenesis and breast cancer metastasis. Histol Histopathol 2002;17(3):863–870.
   PubMed Web of Science ®Google Scholar
• Wang J, Guo Y, Wang B, Bi J, Li K, Liang X, Chu H, Jiang H. Lymphatic microvessel density and vascular endothelial growth factor-C and -D as prognostic factors in breast cancer: a systematic review and meta-analysis of the literature. Mol Biol Rep 2012;39(12):11153–11165. doi: 10.1007 /s11033-012-2024-y.
   PubMed Web of Science ®Google Scholar
• Chen Y, Yan J, Wang Z, Yu S, Yuan Z, Yang C, Zheng Q. A meta-analysis of the relationship between lymphatic microvessel density and the survival of patient with colorectal cancer. Lymphology 2013;46(1):42–51.
   PubMed Web of Science ®Google Scholar
• Yu M, Liu L, Liang C, Li P, Ma X, Zhang Q, Wei Y. Intratumoral vessel density as prognostic factors in head and neck squamous cell carcinoma: a meta-analysis of literature. Head Neck 2013. doi: 10.1002 /hed.23301.
   Web of Science ®Google Scholar
• Pastushenko I, Vermeulen PB, Carapeto FJ, Van den Eynden G, Rutten A, Ara M, Dirix LY, Van Laere S. Blood microvessel density, lymphatic microvessel density and lymphatic invasion in predicting melanoma metastases: systematic review and meta-analysis. Br J Dermatol 2014;170(1):66–77.
   PubMed Web of Science ®Google Scholar
• Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B, Senn HJ. 10th St. Gallen conference. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007;18(7):1133–1144.
   PubMed Web of Science ®Google Scholar
• Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ. (Eds.): WHO Classification of Tumours of the Breast. IARC: Lyon, 2012.
   Google Scholar
• Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. Part I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991;19(5):403–410.
   PubMed Web of Science ®Google Scholar
• Pula B, Wojnar A, Werynska B, Ambicka A, Kruczak A, Witkiewicz W, Ugorski M, Podhorska-Okolow M, Dziegiel P. Impact of different tumour stroma assessment methods regarding podoplanin expression on clinical outcome in patients with invasive ductal breast carcinoma. Anticancer Res 2013;33(4):1447–1455.
   PubMed Web of Science ®Google Scholar
• El-Gendi S, Abdel-Hadi M. Lymphatic vessel density as prognostic factor in breast carcinoma: relation to clinicopathologic parameters. J Egypt Natl Canc Inst 2009;21(2):139–149.
   PubMedGoogle Scholar
• Niemiec J, Adamczyk A, Małecki K, Ambicka A, Ryś J. Tumor grade and matrix metalloproteinase 2 expression in stromal fibroblasts help to stratify the high-risk group of patients with early breast cancer identified on the basis of St Gallen recommendations. Clin Breast Cancer 2013;13(2):119–128.
   PubMed Web of Science ®Google Scholar
• Mehta R, Jain RK, Sneige N, Badve S, Resetkova E. Expression of high-molecular-weight cytokeratin (34betaE12) is an independent predictor of disease-free survival in patients with triple-negative tumours of the breast. J Clin Pathol 2010;63(8):744–747.
   PubMed Web of Science ®Google Scholar
• Hugh J, Hanson J, Cheang MC, Nielsen TO, Perou CM, Dumontet C, Reed J, Krajewska M, Treilleux I, Rupin M, Magherini E, Mackey J, Martin M, Vogel C. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol 2009;27(8):1168–1176.
   PubMed Web of Science ®Google Scholar
• Fountzilas G, Dafni U, Bobos M, Batistatou A, Kotoula V, Trihia H, Malamou-Mitsi V, Miliaras S, Chrisafi S, Papadopoulos S, Sotiropoulou M, Filippidis T, Gogas H, Koletsa T, Bafaloukos D, Televantou D, Kalogeras KT, Pectasides D, Skarlos DV, Koutras A, Dimopoulos MA. Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel. PLoS One 2012;7(6):e37946. doi: 10.1371 /journal.pone.0037946.
   PubMedGoogle Scholar
• Niemiec JA, Adamczyk A, Małecki K, Majchrzyk K, Ryś J. Relationships between Immunophenotype; Ki-67 Index; microvascular density; Ep-CAM/P-cadherin; and MMP-2 expression in early-stage invasive ductal breast cancer. Appl Immunohistochem Mol Morphol 2012;20(6):550–560.
   PubMedGoogle Scholar